December 14, 2016 / 12:56 AM / in 9 months

BRIEF-Helix Biopharma Q1 loss per share C$0.04

Dec 13 (Reuters) - Helix Biopharma Corp

* Helix Biopharma Corp- Considers securing additional funds, expected to be through issuance of equity securities of company, to be of utmost importance

* Helix Biopharma - Cash reserves as at Oct 31, 2016, are insufficient to see current research and development initiatives through to completion.

* Helix Biopharma Corp. announces fiscal first quarter 2017 results

* Q1 loss per share C$0.04

Source text for Eikon:

Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below